SC
EGRX

Sculptor Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Sculptor Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,800
Closed -$406K – 384
2016
Q3 		$406K Buy
+5,800
New +$321K ﹤0.01% 265

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Sculptor Capital's EGRX Position: Q4 2016 in Review

Sculptor Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2016, closing a stake of 5,800 shares — an estimated $406K sold.

Sculptor Capital first reported a position in EGRX in Q3 2016 and held it in 1 quarter. The position peaked at $406K in Q3 2016. 149 funds tracked by Wall St. Rank hold EGRX as of Q4 2016.

  • Sculptor Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Sculptor Capital sold 5,800 Eagle Pharmaceuticals, Inc. shares in Q4 2016, an estimated $406K.
  • Sculptor Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • Sculptor Capital's Eagle Pharmaceuticals, Inc. position peaked at $406K in Q3 2016.
  • 149 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2016.

Based on Sculptor Capital's 13F filing for Q4 2016, filed 10 Feb 2017.